. A guide wire, twice the length of the bronchoscope, was inserted into the applicator to facilitate the careful withdrawal of the bronchoscope, leaving the applicator in situ, secured to the nose with tape. The guide wire was then also withdrawn and another metal wire was advanced to the applicator tip. This wire has radio-opaque graduations at 1 cm intervals over a total length of 27 cm, corresponding to the maximum treatment length that can be programmed with the micro-Selectron (fig 2) . Anteroposterior and lateral chest radiographs were taken with this graduated insert in place. The main carina was identified on the plain radiograph and the 1 cm graduations were used to identify the tumour site and plan the treatment length. The patient was then transferred to the theatre and the applicator connected to the treatment unit. The length of the bronchus to be treated and the source stopping positions within the applicator were calculated on the basis of information gained from the pretreatment radiographs, bronchoscopy, and the localisation films. The iridium source was programmed to advance in 5 mm steps along the chosen treatment length, and the dwell time in each position was determined by the strength ofthe source and the prescribed dose. A single exposure of 15-20 Gy at a 10 mm radius from the centre of the applicator was given, each treatment lasting 10-25 minutes. At the end of the treatment session the applicator was disconnected from the treatment unit and manually withdrawn.
Results
Forty six patients were available for the analysis at 6 weeks; four patients had died by this time. Fourteen patients in total have died, one from renal failure, three from cardiovas- The results of the symptomatic, radiological, and bronchoscopic assessments are shown in the table. Twenty four of the 28 patients with haemoptysis showed substantial improvement and 22 obtained a complete response. The earliest recurrence occurred at 4 months; at that time 19 of the 21 responders still alive were in remission. Haemoptysis has recurred or progressed in three patients, minor in two (at 4 and 6 months) and more severe in one (at 4 months). Only four patients, some five months after intraluminal irradiation, have required of external beam radiotherapy for the treatment of troublesomie recurrent thoracic symptoms.
Discussion
Palliative external beam radiotherapy is widely used to relieve symptoms arising from the f primary tumour in incurable carcinoma of the bronchus. Haemoptysis, shortness of breath, and cough are caused principally by the endobronchial component and should be improved by treatment capable of clearing the bronchi of macroscopic disease. This study has shown that effective palliation of haemoptysis (24 of28 patients), dyspnoea (21 of33 patients), and cough (nine of 18 patients) can be achieved with a single exposure of high dose rate intraluminal radiotherapy given under local anaesthesia as a day case procedure. The responses were maintained for at least four months and only four of the 46 surviving patients so far have needed further radiotherapy for the relief of new or recurrent thoracic symptoms. It is a safe treatment with no deaths related to treatment and hardly any morbidity.
Repeat bronchoscopy was performed in 17 patients in the early part of the study. Impressive clearing of tumour was found in 15, with no residual disease seen at biopsy in many cases. Complete or partial re-expansion of collapsed lung was observed in 1 1 of 24 patients (figs 3 and 4). Forty one patients had a repeat chest radiograph at their first post-treatment assessment. Although the appearances had wing deteriorated in 14, the aims of treatment were achieved in six of these patients as their symp-toms had improved with resolution of the endobronchial component of the disease.
These response rates compare very favourably with the results of conventional external beam therapy. The relief of haemoptysis, breathlessness, and cough is similar to that reported with external beam radiotherapy,34 whereas re-expansion of collapsed lung was almost twice as good.5 The duration ofresponse and survival pattern appear to be similar and these benefits were achieved without the acute oesophagitis and tiredness that occurs in 80% of patients who have conventional treatment. 3 Laser resection of endobronchial tumour also produces effective palliation. The relief of symptoms may be quicker but the procedure is certainly more demanding for patient and doctor and associated with more morbidity, and may produce a shorter duration of response.6
Intraluminal irradiation and laser resection should perhaps be regarded as complementary rather than alternative treatments. In most cases intraluminal irradiation will suffice but in others, perhaps where there is pulmonary collapse, prior laser resection may enhance the degree of palliation. More experience should enable us to determine which treatment or combination of treatments provides the best palliation with the least morbidity.
The success of this pilot study has encouraged us to start a randomised clinical trial comparing intraluminal radiotherapy with external beam radiotherapy for patients with symptoms due to endobronchial disease alone. A further trial will compare extemal beam radiotherapy alone with external beam radiotherapy plus intraluminal irradiation in patients who have additional symptoms due to the mass effect of the tumour.
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